{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:27:49Z","timestamp":1786969669985,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Tumor-infiltrating lymphocytes (TILs) are emerging as key biomarkers in invasive breast carcinoma (IBC), reflecting the host immune response and influencing prognosis. While TILs are well-studied globally, data from the Indian subcontinent remains scarce. This study assesses stromal TILs (sTILs) and intratumoral TILs (iTILs) in an Indian cohort, investigating their associations with pathological features, clinical stage, and molecular subtypes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective observational study of consecutive IBC patients at a single Indian cancer center was conducted over two years and included. Demographic, pathological, and immunohistochemical (IHC) data (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 [HER2], Ki67 proliferation index) were collected. TILs were evaluated on Hematoxylin and eosin (H and E) slides using International TILs Working Group (ITILWG) guidelines: sTILs expressed as a percentage of stromal area and iTILs semi-quantitatively (0\u2013300). Correlations and group comparisons were analyzed using Spearman\u2019s rank correlation, Kruskal-Wallis tests, and multivariable linear regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 326 patients were included. The median sTIL percentage was 7% (interquartile range [IQR] 5\u201338), and the median iTIL score was 60 (IQR 20\u2013130). Higher median sTIL and iTIL levels were observed in triple-negative and HER2-enriched tumors, high-grade cancers, and hormone receptor\u2013negative disease. Median sTIL percentages increased with tumor grade (grade 1: 5% [IQR 5\u20135]; grade 3: 35% [IQR 9\u201360]). Similar patterns were observed for iTILs. After Holm adjustment, associations with nuclear pleomorphism, mitotic activity, tumor grade, molecular subtype, Ki-67 category, and hormone receptor status remained statistically significant. In multivariable analyses using log-transformed TILs, molecular subtype and tumor grade were independently associated with higher sTIL and iTIL levels, while stage IV disease was associated with lower TIL levels compared with stage II.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study confirms a strong correlation between sTILs and iTILs, suggesting sTIL assessment alone may suffice for routine practice. Higher TIL levels were significantly linked to more aggressive pathological features, such as higher tumor grade and triple-negative\/HER2-enriched subtypes. While TIL levels varied with clinical stage, no consistent monotonic relationship was observed. Future research should integrate other biomarkers predictive of immunotherapy response and establish clinically actionable TIL cut-off values.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1656_25","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T08:00:19Z","timestamp":1786780819000},"page":"582-589","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Tumor-infiltrating lymphocytes density and distribution in breast cancer: A two-year study on their clinicopathological correlation"],"prefix":"10.4103","volume":"22","author":[{"given":"Yamuna","family":"Jayakumar","sequence":"first","affiliation":[{"name":"Department of Pathology, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha","family":"Abraham","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Subi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teena","family":"Sleeba","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanju","family":"Cyriac","sequence":"additional","affiliation":[{"name":"Medical Oncology, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Paul","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Harish","family":"Somasundaram","sequence":"additional","affiliation":[{"name":"Nuclear Medicine, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"John","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Ebin","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Rajagiri Cancer Centre, Rajagiri Hospital, Kochi, Kerala, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"R1-20260817","first-page":"2929","article-title":"Breast cancer intrinsic subtype classification, clinical use and future trends","volume":"5","author":"Dai","year":"2015","journal-title":"Am J Cancer Res"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/PAI.0000000000000466","article-title":"Prognostic significance of stromal versus intratumoral infiltrating lymphocytes in different subtypes of breast cancer treated with cytotoxic neoadjuvant chemotherapy","volume":"26","author":"Khoury","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","article-title":"Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: A secondary analysis of the NeoALTTO trial","volume":"1","author":"Salgado","year":"2015","journal-title":"JAMA Oncol"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor-infiltrating lymphocytes are prognostic in triple-negative breast cancer and predictive for trastuzumab benefit in early breast cancer: Results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamaoncol.2015.3239","article-title":"Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer","volume":"2","author":"Perez","year":"2016","journal-title":"JAMA Oncol"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes in breast cancer: Recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"241","DOI":"10.32768\/abc.2023103241-247","article-title":"Tumor-infiltrating lymphocytes and tumor budding in invasive breast carcinoma: Correlation with known prognostic parameters","volume":"10","author":"Bandyopadhyay","year":"2023","journal-title":"Arch Breast Cancer"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13000-022-01271-y","article-title":"Evaluation of tumor-infiltrating lymphocytes in molecular subtypes of an Indian cohort of breast cancer patients","volume":"17","author":"Vaid","year":"2022","journal-title":"Diagn Pathol"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/bcr2607","article-title":"Breast cancer prognostic classification in the molecular era: The role of histological grade","volume":"12","author":"Rakha","year":"2010","journal-title":"Breast Cancer Res"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"144","author":"Allison","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\/CAP focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000351692","article-title":"13th St. Gallen International Breast Cancer Conference 2013: Primary therapy of early breast cancer\u2014evidence, controversies, consensus","volume":"8","author":"Untch","year":"2013","journal-title":"Breast Care (Basel)"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/BD-200442","article-title":"Evaluation of tumor-infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage","volume":"39","author":"Pujani","year":"2020","journal-title":"Breast Dis"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: Pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-016-3863-3","article-title":"Tumor-infiltrating lymphocytes as a prognostic marker in triple-negative breast cancer","volume":"158","author":"Pruneri","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3390\/biomedicines12040763","article-title":"Tumor-infiltrating lymphocytes in breast cancer: Prognostic and predictive significance across molecular subtypes","volume":"12","author":"Ciarka","year":"2024","journal-title":"Biomedicines"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s10555-021-09968-0","article-title":"Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer","volume":"40","author":"Nelson","year":"2021","journal-title":"Cancer Metastasis Rev"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.3390\/cancers15184479","article-title":"Tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer: Review of current evidence and prognostic implications","volume":"15","author":"Angelico","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/annonc\/mdy518","article-title":"Pembrolizumab monotherapy for untreated PD-L1-positive metastatic triple-negative breast cancer (KEYNOTE-086 cohort B)","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-086 cohort A)","volume":"30","author":"Adams","year":"2019","journal-title":"Ann Oncol"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(20)30754-3","article-title":"Pembrolizumab versus chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119)","volume":"22","author":"Winer","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1656_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:01:33Z","timestamp":1786968093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1656_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1656_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"2025-08-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}